Treatment of facial seborrheic dermatitis with pimecrolimus cream 1%: An open-label clinical study in Korean patients

Journal of Korean Medical Science

Volumn 22, Issue 5, 2007, Pages 868-872

  Kim, Byung Soo ^a   Kim, Su Han ^b   Kim, Moon Bum ^b,d   Oh, Chang Keun ^b   Jang, Ho Sun ^c   Kwon, Kyung Sool ^b  

^a Kyungpook National University   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Mok Hye Su Jang Ho Sun Dermatology Clinic   (South Korea)

^d Pusan National University   (South Korea)

Author keywords

Dermatitis; Pimecrolimus; Seborrheic

Indexed keywords

EID: 36148929382     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2007.22.5.868     Document Type: Article

References (19)

1. Fritsch PO, Reider N. Other Eczematous Eruption. In: Bolognia JL, Jorizzo JL, Rapini RP, editors, Dermatology. Philadelphia: Mosby, 2003; 215-26.
2. Plewig G, Jansen T. Seborrheic Dermatitis. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, editors, Fitzpatrick's Dermatology in General medicine. New York: McGraw-Hill, 2003; 1198-204.
3. Green CA, Farr PM, Shuster S. Treatment of seborrhoeic dermatitis with ketoconazole: II. Response of seborrhoeic dermatitis of the face, scalp and trunk to topical ketoconazole. Br J Dermatol 1987; 116: 217-21.
4. Pierard-Franchimont C, Pierard GE. A double-blind placebo-controlled study of ketoconazole+desonide gel combination in the treatment of facial seborrheic dermatitis. Dermatology 2002; 204: 344-7.
5. Faergemann J. Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol 2000; 1: 75-80.
6. Park EJ, Kim CW, Kim KH, Ahn KJ, Kim KJ. Therapeutic effect of itraconazole in seborrheic dermatitis. Korean J Med Mycol 2004; 9: 222-9.
7. Gupta AK, Chow M. Pimecrolimus: a review. J Eur Acad Dermatol Venereol 2003; 17: 493-503.
8. Crutchfield CE 3rd. Pimecrolimus: a new treatment for seborrheic dermatitis. Cutis 2002; 70: 207-8.
9. Rigopoulos D, Ioannides D, Kalogeromitros D, Gregoriou S, Katsambas A. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. Br J Dermatol 2004; 151: 1071-5.
10. Rallis E, Nasiopoulou A, Kouskoukis C, Koumantaki E. Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk. Drugs Exp Clin Res 2004; 30: 191-5.
11. Brownell I, Quan LT, Hsu S. Topical pimecrolimus in the treatment of seborrheic dermatitis. Dermatol Online J 2003; 9: 13.
12. Braza TJ, DiCarlo JB, Soon SL, McCall CO. Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. Br J Dermatol 2003; 148: 1242-4.
13. Meshkinpour A, Sun J, Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol 2003; 49: 145-7.
14. Faergemann J, Jones JC, Hettler O, Loria Y. Pityrosporum ovale (Malassezia furfur) as the causative agent of seborrheic dermatitis: new treatment options. Br J Dermatol 1996; 134 (Suppl 46): 12-5.
15. Neuber K, Kroger S, Gruseck E, Abeck D, Ring J. Effects of Pityrosporum ovale on proliferation, immunoglobulin (IgA, G, M) synthesis and cytokine (IL-2, IL-10, IFN gamma) production of peripheral blood mononuclear cells from patients with seborrhoeic dermatitis. Arch Dermatol Res 1996; 288: 532-6.
16. Faergemann J. Pityrosporum species as a cause of allergy and infection. Allergy 1999; 54: 413-9.
17. Sugita T, Tajima M, Ito T, Saito M, Tsuboi R, Nishikawa A. Antifungal activities of tacrolimus and azole agents against the eleven currently accepted Malassezia species. J Clin Microbiol 2005; 43: 2824-9.
18. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, Bush C, Graeber M. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495-504.
19. Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, Ortonne JP. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001; 144: 507-13.